Reset filter
Palabras clave
Schizofrene stoornissen ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
    1. 7.1. Anestesiología
    1. 7.2. Dermatología
    1. 7.3. ENT
    1. 7.4. Geriatría
    1. 7.5. Ginecología / Obstetricia
    1. 7.6. Medicina Interna
      1. Hematología
      1. Enfermedades infecciosas
      1. Cardiología / Angiología
      1. Neumología
      1. Gastroenterología
      1. Nefrología
      1. Endocrinología / Enfermedades metabólicas
      1. Reumatología
    1. 7.7. Neurología
    1. 7.8. Oftalmología
    1. 7.9. Cuidados paliativos
    1. 7.10. Patología / Forense
    1. 7.11. Pediatría
    1. 7.12. Psiquiatría / Psicosomática
    1. 7.13. Radiología
    1. 7.14. Cirugía
      1. Cirugía General / Visceral
      1. Neurocirugía
      1. Cirugía plástica
      1. Cirugía Torácica
      1. Traumatología / Ortopedia
      1. Cirugía vascular
    1. 7.15. Urología
    1. 7.16. Odontología / OMS
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

15 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

dbGaP phs000944 eMERGE Clinical Center at Partners HealthCare - Eligibility

- 27/11/24 - 6 formularios, 2 itemgroups, 11 items, 1 idioma
Itemgroups: IG.elig, IG.elig
Principal Investigator: Scott T. Weiss, MD, MS, Partners HealthCare System, Boston, MA, USA MeSH: Hypercholesterolemia,Asthma,Arthritis, Rheumatoid,Attention Deficit Disorder with Hyperactivity,Bipolar Disorder,Coronary Disease,Depression,Heart Failure,Inflammatory Bowel Diseases,Multiple Sclerosis,Schizophrenia,Stroke https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000944 The Partners HealthCare Biobank is a large research data and sample repository working within the framework of Partners Personalized Medicine. It provides researchers access to high quality, consented samples to help foster research, advance understanding of the causes of common diseases, and advance the practice of medicine. The Partners Biobank provides banked samples (plasma, serum and DNA) collected from consented patients. These samples are available for distribution to Partners HealthCare investigators with appropriate approval from the Partners Institutional Review board (IRB). They are linked to clinical data that originates in the Electronic Medical Record (EMR), as well as additional health information collected in a self-reported survey. The Partners Biobank will be genotyping 25,000 subjects with the Illumina Multiethnic Beadchip 1.6 million SNPs with exome and custom content ( 60,000 LoFs). Of the participants genotyped so far, 4929 of 4962 (99.3%) individuals have genotype data that passed the default quality thresholds for the Infinium array (call rate = 0.99). We are submitting the genotype data to dbGaP for 4929 subjects with 12 phenotypes (based on icd9 codes). We will do annual releases until we reach the full 25,000 genotyped subjects.

pht004847.v1.p1

1 itemgroup 5 items

pht005288.v1.p1

1 itemgroup 6 items

pht004844.v1.p1

1 itemgroup 2 items

pht004845.v1.p1

1 itemgroup 3 items

pht004846.v1.p1

1 itemgroup 18 items

Eligibility Schizophrenia NCT00645099

- 1/9/17 - 1 formulario, 2 itemgroups, 15 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT00645099

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Liver Events Assessment

- 17/12/19 - 1 formulario, 2 itemgroups, 3 items, 1 idioma
Itemgroups: Administrative documentation, Liver, Adverse event, Evaluation
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Day 1

- 17/12/19 - 1 formulario, 19 itemgroups, 83 items, 1 idioma
Itemgroups: Administrative documentation, Allen test, Vital signs, Pulmonary function tests, 12 lead ECG, Holter Electrocardiography, Positron-Emission Tomography, Pre-dose, Pharmacokinetic aspects - Blood, Randomization, Numbers, Therapeutic procedure, Confirmation, Experimental drug, Positron-Emission Tomography, Post-dose, Physical Examination, Post-dose, Vital signs, Post-dose, Laboratory Procedures, Post-dose, Hematology finding, Laboratory Procedures, Post-dose, Chemistry, Clinical, Urinalysis, Post-dose, Laboratory Procedures, Post-dose, Renal function, Blood, Laboratory Procedures, Post-dose, Renal function, Urine
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Eligibility Schizophrenia NCT00205738

- 10/2/16 - 1 formulario, 2 itemgroups, 9 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Janssen - Glucose Regulation/Risp/Olanz; ODM derived from: https://clinicaltrials.gov/show/NCT00205738

Eligibility Schizophrenia NCT00205725

- 10/2/16 - 1 formulario, 2 itemgroups, 15 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pfizer/IVGTT/Ziprasidone/Olanzapine; ODM derived from: https://clinicaltrials.gov/show/NCT00205725

The relationship of Glycine Transporter1 occupancy by GSK1018921 to plasma concentrations over time NCT00945503 - Screening - Serology HIV Screen; Laboratory Result Data; Urinalysis

- 5/6/19 - 1 formulario, 9 itemgroups, 19 items, 1 idioma
Itemgroups: Administrative Data, Serology - HIV Screen, Laboratory Result Data (Haematology), Haematology Test Result, Laboratory Result Data (Clinical Chemistry), Clinical Chemistry Test Result, Urinalysis, Urinalysis (Dipstick) Test Result, Urinalysis (Microscopy) Test Result
Study ID: 109731 Clinical Study ID: 109731 Study Title: An adaptive PET study in healthy volunteers using 11C GSK931145 to establish the relationship of Glycine Transporter1 occupancy by GSK1018921 to plasma concentrations over time Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00945503 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1018921

dbGaP phs000837 Whole Genome Sequencing of Two 22q11DS Trios - pht004442.v1.p1

- 9/3/24 - 6 formularios, 1 itemgroup, 6 items, 1 idioma
Itemgroup: pht004442
Principal Investigator: Bernice Morrow, PhD, Albert Einstein College of Medicine, Bronx, NY, USA MeSH: Tetralogy of Fallot,Psychotic Disorders,Schizophrenia,Arthritis, Juvenile https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000837 Two subjects with 22q11.2 deletion syndromes (22q11DS) and their parents were recruited for a whole genome sequencing study to identify candidate genetic modifiers of the various phenotypes seen in 22q11DS. Both probands had a typical 3 megabase deletion on chromosome 22q11.2 but discordant phenotypes.

pht004441.v1.p1

1 itemgroup 6 items

pht004440.v1.p1

1 itemgroup 5 items

Eligibility

1 itemgroup 2 items

pht004438.v1.p1

1 itemgroup 5 items

pht004439.v1.p1

1 itemgroup 5 items

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Follow-up

- 17/12/19 - 1 formulario, 11 itemgroups, 44 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs, Pulmonary function tests, 12 lead ECG, Physical Examination, Vital signs, Laboratory Procedures, Hematology finding, Laboratory Procedures, Chemistry, Clinical, Urinalysis, Laboratory Procedures, Renal function, Blood, Laboratory Procedures, Renal function, Urine
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Day -1

- 15/12/19 - 1 formulario, 11 itemgroups, 40 items, 1 idioma
Itemgroups: Administrative documentation, Vital signs, Holter Electrocardiography, Physical Examination, Urine drug screening; Ethanol measurement, breath test expired carbon monoxide, Laboratory Procedures, Hematology finding, Laboratory Procedures, Chemistry, Clinical, Urinalysis, Laboratory Procedures, Renal function, Blood, Laboratory Procedures, Renal function, Urine
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Screening

- 15/12/19 - 1 formulario, 23 itemgroups, 125 items, 1 idioma
Itemgroups: Administrative documentation, Demography, Vital signs, Disease, Physical Examination, Allen test, Alcohol consumption, Urine drug screening; Ethanol measurement, breath test expired carbon monoxide, Serologic tests, Mini International Neuropsychiatric Interview, Laboratory Procedures, Hematology finding, Laboratory Procedures, Chemistry, Clinical, Urinalysis, Laboratory Procedures, Renal function, Blood, Laboratory Procedures, Renal function, Urine, 12 lead ECG, Holter Electrocardiography, Eligibility Determination, Inclusion, Exclusion Criteria, 12 lead ECG, Abnormality, Holter Electrocardiography, Abnormality
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

The relationship of Glycine Transporter1 occupancy by GSK1018921 to plasma concentrations over time NCT00945503 - Day 1 - Vital Signs; 12-Lead ECG; Laboratory Results Data (Haematology, Clinical Chemistry) - Pre-Dose and 24h Post-Dose; Urinalysis - Pre-Dose and 24h Post-Dose; Randomisation Number; Investigational Product; Treatment Confirmation; PET Scan (2); fMRI Scan - Post-PET Scan; PET Scan (3); Pharmacokinetics - Blood

- 6/4/22 - 1 formulario, 16 itemgroups, 158 items, 1 idioma
Itemgroups: Administrative, Vital Signs, 12-Lead ECG, Laboratory Results Data (Haematology) - Pre-Dose, Laboratory Results Data (Clinical Chemistry) - Pre-Dose, Urinalysis - Pre-Dose, Randomisation Number, Investigational Product, Treatment Confirmation, PET Scan (2), fMRI Scan - Post-PET Scan, PET Scan (3), Pharmacokinetics - Blood, Laboratory Results Data (Haematology) - 24hrs Post-Dose, Laboratory Result Data (Clinical Chemistry) - 24hrs Post-Dose, Urinalysis - 24hrs Post-Dose
Study ID: 109731 Clinical Study ID: 109731 Study Title: An adaptive PET study in healthy volunteers using 11C GSK931145 to establish the relationship of Glycine Transporter1 occupancy by GSK1018921 to plasma concentrations over time Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00945503 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1018921 Study Indication: Schizophrenia

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial